Cathay International Holdings Ld Lansen's proposal to approve a special dividend (4066H)
07 June 2017 - 7:14PM
UK Regulatory
TIDMCTI
RNS Number : 4066H
Cathay International Holdings Ld
07 June 2017
Cathay International Holdings Limited
("Cathay", the "Company" or the "Group")
Lansen's proposal to approve the declaration and payment of a
special dividend
Hong Kong, 7 June 2017 - Cathay International Holdings Ltd.
(LSE: CTI.L), an operator and investor in the growing healthcare
sector in the People's Republic of China, announces that its
subsidiary Lansen Pharmaceutical Holdings Ltd ("Lansen") (HKEX:
503), in which the Company has a 50.56% holding, has announced in
Hong Kong today that a meeting of the board of directors of Lansen
(the "Lansen Board") will be held on Monday, 19 June, 2017 to
consider the recommendation, declaration and payment of a special
dividend. Lansen will make a further announcement after the Lansen
Board meeting to set out the details of the special dividend, if
approved by the Lansen Board.
There can be no guarantee that any proposed special dividend
will be approved by the Lansen Board at the Lansen Board meeting or
that the other conditions for the declaration and payment of a
proposed special dividend will be fulfilled.
The full text of the Lansen Announcement can be found at
http://www.hkexnews.hk/listedco/listconews/SEHK/2017/0607/LTN20170607253.pdf
and will also be made available at the Announcements & Notices
section of Lansen's homepage at
http://www.lansen.com.cn/En/Announcements&Notices.asp.
-ENDS-
For further enquiries, please contact:
Cathay International Holdings Limited
Eric Siu (Finance Director) Tel: +852 2828 9289
Patrick Sung (Director and Controller)
N+1 Singer
Aubrey Powell/ Lauren Kettle - Corporate Finance Tel: +44 (0) 20 7496 3000
Brough Ransom - Sales
Consilium Strategic Communications
Mary-Jane Elliott/ Matthew Neal / Lindsey Neville Tel: +44 (0) 203 709 5700
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main
market listed investment holding company and an operator and
investor in the growing healthcare sector in the People's Republic
of China (the "PRC"). The Company and its subsidiaries
(collectively the "Group") aim to leverage on growth opportunities
in the strong and growing domestic demand for high quality
healthcare products in the PRC and build its portfolio companies
into market sector leaders with competitive edge. Cathay has
already demonstrated a strong track record of identifying high-
growth potential investment opportunities in this area including:
Lansen, a leading specialty pharmaceutical company focused on
rheumatology and dermatology in the PRC; Haizi, a company engaged
in the manufacture, marketing and sale of inositol and its
by-product, di-calcium phosphate; Natural Dailyhealth, a company
engaged in production and sales of plant extracts for use as key
active ingredients in healthcare products; and Botai, a company
engaged in collagen products.
The Group employs approximately 2,000 people across the PRC,
including over 30 specialist corporate and business development
staff based at the holding company's offices in Hong Kong and
Shenzhen. Cathay also has a hotel investment. For more information
please visit the Company's website: www.cathay-intl.com.hk.
About Lansen
Lansen, whose shares are listed on the mainboard of the Hong
Kong Stock Exchange, is a 50.56% owned subsidiary of Cathay. Lansen
is engaged in the manufacture, distribution and development of
specialty prescription drugs for treatment of autoimmune disorder
in rheumatology and dermatology. Lansen is in the leading market
position in disease modifying anti-rheumatic drugs ("DMARDs") for
treatment of rheumatoid arthritis ("RA") in the PRC. Lansen has
established an extensive distribution network, covering more than
1,000 hospitals in four municipalities, 25 provinces and cities in
the PRC. For more information please visit the Lansen's website:
http://www.lansen.com.cn/En/index.asp.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DIVLIFIARAIDIID
(END) Dow Jones Newswires
June 07, 2017 05:14 ET (09:14 GMT)
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From Apr 2024 to May 2024
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From May 2023 to May 2024